Phase I study of oral cyclophosphamide and oral topotecan for children with recurrent or refractory solid tumors
暂无分享,去创建一个
P. Leavey | N. Winick | G. Tomlinson | D. Bowers | J. Journeycake | V. Aquino | R. Bash | A. Mulne | Patrick J. Leavey | Robert O. Bash | Arlynn F. Mulne | Heidi J. Haynes | Heidi J. Haynes
[1] N. Cheung,et al. Oral Topotecan for Refractory and Relapsed Neuroblastoma: A Retrospective Analysis , 2003, Journal of pediatric hematology/oncology.
[2] Eugene S. Kim,et al. Topotecan is anti-angiogenic in experimental hepatoblastoma. , 2002, Journal of pediatric surgery.
[3] Peter Bohlen,et al. Antitumor effects in mice of low-dose (metronomic) cyclophosphamide administered continuously through the drinking water. , 2002, Cancer research.
[4] Eugene S. Kim,et al. Distinct response of experimental neuroblastoma to combination antiangiogenic strategies. , 2002, Journal of pediatric surgery.
[5] Takashi Tsuruo,et al. Topotecan inhibits VEGF‐ and bFGF‐induced vascular endothelial cell migration via downregulation of the PI3K‐Akt signaling pathway , 2002, International journal of cancer.
[6] A. Goldhirsch,et al. Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.
[7] W. Middlesworth,et al. Novel use of an established agent: Topotecan is anti-angiogenic in experimental Wilms tumor. , 2001, Journal of pediatric surgery.
[8] R. Kerbel,et al. Antiangiogenic scheduling of lower dose cancer chemotherapy. , 2001, Cancer journal.
[9] P. Meyers,et al. Pilot study of topotecan and high-dose cyclophosphamide for resistant pediatric solid tumors. , 2000, Medical and pediatric oncology.
[10] E Glatstein,et al. High-time chemotherapy or high time for low dose. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] L. Ellis,et al. Chemotherapeutic drugs—more really is not better , 2000, Nature Medicine.
[12] Peter Bohlen,et al. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity , 2000 .
[13] J. Folkman,et al. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. , 2000, Cancer research.
[14] M. Harris,et al. #465 Cyclophosphamide plus topotecan in children with recurrent or refractory solid tumors: a pediatric oncology group (POG) phase II study , 1999 .
[15] D. Ribatti,et al. Purine analogue 6-methylmercaptopurine riboside inhibits early and late phases of the angiogenesis process. , 1999, Cancer research.
[16] M. Cumming,et al. Antiangiogenic potential of camptothecin and topotecan , 1999, Cancer Chemotherapy and Pharmacology.
[17] M. Tan,et al. Interpatient variability in bioavailability of the intravenous formulation of topotecan given orally to children with recurrent solid tumors , 1999, Cancer Chemotherapy and Pharmacology.
[18] H. Cohen,et al. Antiangiogenic effects of camptothecin analogues 9-amino-20(S)-camptothecin, topotecan, and CPT-11 studied in the mouse cornea model. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.
[19] A. Cnaan,et al. Synergistic cytotoxicity of topoisomerase I inhibitors with alkylating agents and etoposide in human brain tumor cell lines. , 1998, Anti-cancer drugs.
[20] C. Stewart,et al. Phase I study of topotecan in combination with cyclophosphamide in pediatric patients with malignant solid tumors: a Pediatric Oncology Group Study. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] H. McDowell,et al. High-dose cyclophosphamide for poor-prognosis and recurrent pediatric brain tumors: a dose-escalation study. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] D. Zelterman,et al. Dose-escalation and pharmacodynamic study of topotecan in combination with cyclophosphamide in patients with refractory cancer. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] R. D'Amato,et al. Inhibition of angiogenesis and breast cancer in mice by the microtubule inhibitors 2-methoxyestradiol and taxol. , 1997, Cancer research.
[24] L. Grochow,et al. Factors Affecting Topotecan Sensitivity in Human Leukemia Samples a , 1996, Annals of the New York Academy of Sciences.
[25] J. Kurtzberg,et al. Phase I Trial and Pharmacokinetic (PK) and Pharmacodynamics (PD) Study of Topotecan Using a Five‐Day Course in Children with Refractory Solid Tumors: A Pediatric Oncology Group Study , 1996, Journal of pediatric hematology/oncology.
[26] S. Steinberg,et al. Ifosfamide and etoposide plus vincristine, doxorubicin, and cyclophosphamide for newly diagnosed Ewing's sarcoma family of tumors , 1996, Cancer.
[27] E. Gehan,et al. Cyclophosphamide Dose Escalation in Combination with Vincristine and Actinomycin‐D (VAC) in Gross Residual Sarcoma: A Pilot Study Without Hematopoietic Growth Factor Support Evaluating Toxicity and Response , 1995, Journal of pediatric hematology/oncology.
[28] D. Venzon,et al. A Phase I and II Trial of Dose‐Intensified Cyclophosphamide and GM‐CSF in Pediatric Malignant Brain Tumors , 1995, Journal of pediatric hematology/oncology.
[29] N. Breslow,et al. Treatment of children with stages II to IV anaplastic Wilms' tumor: a report from the National Wilms' Tumor Study Group. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[30] W. Furman,et al. Phase I study of topotecan for pediatric patients with malignant solid tumors. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[31] S. Chatterjee,et al. Schedule-dependent cytotoxicity of topotecan alone and in combination chemotherapy regimens. , 1994, Oncology research.
[32] F. Balis,et al. Pediatric phase I trial and pharmacokinetic study of topotecan administered as a 24-hour continuous infusion. , 1993, Cancer research.
[33] E K Rowinsky,et al. The current status of camptothecin analogues as antitumor agents. , 1993, Journal of the National Cancer Institute.
[34] J. Champoux,et al. Overexpression of human topoisomerase I in baby hamster kidney cells: hypersensitivity of clonal isolates to camptothecin. , 1992, Cancer research.
[35] J. Shuster,et al. Postoperative treatment of nonmetastatic visible residual neuroblastoma: a Pediatric Oncology Group study. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[36] J. Wang,et al. Expression of human DNA topoisomerase I in yeast cells lacking yeast DNA topoisomerase I: restoration of sensitivity of the cells to the antitumor drug camptothecin. , 1989, Cancer research.
[37] B. Teicher,et al. Influence of schedule on alkylating agent cytotoxicity in vitro and in vivo. , 1989, Cancer research.
[38] L. Liu,et al. Arrest of replication forks by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin. , 1989, Cancer research.
[39] R. Saura,et al. Inhibition of in vitro vascular endothelial cell proliferation and in vivo neovascularization by low-dose methotrexate. , 1989, Arthritis and rheumatism.
[40] T. Wagner,et al. Pharmacokinetics of “activated” cyclophosphamide and therapeutic efficacies , 1984, Cancer.
[41] E. Frei,et al. Dose: a critical factor in cancer chemotherapy. , 1980, The American journal of medicine.
[42] M. D’Incalci,et al. Decreased half life of cyclophosphamide in patients under continual treatment. , 1979, European journal of cancer.
[43] J. Finklestein,et al. Evaluation of a high dose cyclophosphamide regimen in childhood tumors , 1969, Cancer.